Year-end report 2015/2016March, 2016

2

AddLife introduction

AddLife is the spin-off of Addtech’s Life Science business area

Listed on Nasdaq Stockholm March 16, 2016

AddLife is a leading independent player in the Nordic Life Science market

AddLife markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector in the Nordics

The company consist of ~25 subsidiaries that operate within two business areas: Labtech and Medtech

Headquartered in Stockholm, approx. 425 employees

Sweden37%

Denmark25%

Finland21%

Norway16%

Other2%

Net sales split per country 9m to Dec. 31, 2015 (4)

Other markets/operations

Production plant

Key markets

3

13 14 15 16 16 18

11 11 11 10 12

13 7

7 8 8 8

9

5 6 6 6

6

7

36 39 39 40

42

49

2010 2011 2012 2013 2014 2018e

Market overview – AddLife’s addressable market

SEKbn Sweden is the largest Life Science market in the Nordic region with ~37% of sales, followed by Denmark with 28% of sales, Norway 19% and Finland 15% (2014)

The market is expected to grow with a CAGR of 4% during the period 2014-2018e, primarily driven by:

‒ Increasing and aging population

‒ Increased use of diagnostics

‒ Digitalization and growing market for e-health

The market is mainly publicly financed and as such affected by:

‒ Public finances

‒ Political decisions

‒ Changes in public procurement policies and processes

4

AddLife’s customer offering – built on 4 cornerstones

Products from leading suppliers

Qualified advisory services on products and solutions

Strong local service and support organization

Training services for customers

5

40%

AddLife’s two business areas - OverviewA

ddLi

fe

60%

LabTech

MedTech

Instruments and reagents for research and

diagnosing diseases

Key products

Medical technology equipment, consumables

and instruments

Key products

Counties and private hospitals

Key customers

Healthcare and research laboratories

Key customers

AddLife’s subsidiaries

AddLife’s subsidiaries

Diagnostics Biomedical & Research

Percentage of net sales

Percentage of net sales

6

AddLife’s two business areas – Offering and business modelLabtech business area Medtech business area

~10 companies focused on niche segments within Medtech

Products are used within for example: Surgery, Wound care, Thorax/neuro, Radiology/cardiology, Intensive care, Ear-nose-throat, Ostomy care and Home health care

Solutions also include service, support and consulting

>90% of sales stem from public procurement

~20% of sales within Medtech stem from sale of own proprietary products

~15 companies focused on niche segments within diagnostics and biomedical & research

The Labtech segment offers: Instruments, Reagents, Consumables, Technical advice, Application-, maintenance-and resupply services and Training

The majority of sales within the Labtech segment is subject to public procurement, approx. 90% within Diagnostics and 70% within Biomedical & Research

One segment, two business models

Inst

rum

ents

Reag

ents

Diagnostics Biomedical & Research

20% 80%

80% 20%

~20% of revenue within Medtech from own products…(2)

Hospidana (Maribo)

Produces tubular, fixation and support bandages

Sataside (Pori)

Produces absorbent wipes

Mediplast (Roncanova)

Produces ICU products

The remaining 2/3 of Medtech´s own products are outsourced to external manufacturing partners in Asia

… of which 1/3 are produced at AddLife’s 3 production facilities…

7

Financial targets

Profitability shall exceed 45%, measured as the relationship between EBITA and working capital (P/WC)

Profit growth (EBITA) shall, long term, amount to 15% per year

The Board of AddLife aims to propose a dividend equivalent to 30-50% of profit after tax. When determining the dividend, investment needs and other factors that the Company's Board of Directors considers relevant are taken into account

Profitability

Profit growth

Dividend policy

8

AddLife’s three strategies to reach its financial and operational goals

Market leading positions

AddLife’s subsidiaries should be market leaders and add value in selected niches

Target niches with high knowledge and technology content

Important for AddLife to be market leading to achieve sustainable earnings growth and profitability

1 Operating mobility

Flexible and agile subsidiaries in order to take advantage of new business opportunities in a fast moving market

Active ownership to drive profitability and business development

Includes moving, merging or splitting subsidiaries and forming better combinations

2 Acquisitions

Integral for the development of the organization and for reaching the profit growth target (EBITA) of 15%

AddLife continuously searches for new Life Science companies which can add:

‒ New products or access to new markets

‒ Strengthen the market position

‒ Strong market and technological know-how

3

9

Decentralized organization with entrepreneurial business acumen

Combine the small company’s…

With the large company’s…

Flexibility

Personality

Effectiveness

Resources

Network

Sustainability

”Small scale business – large

scale wise”

Financials 2015/2016

11

Highlights 2015/16

Spin-off from Addtech & listed on Nasdaq Stockholm March 16

Continued profitable growth Full year - organic growth 5 %, acquired growth 44 % Q4 organic growth 6 %, acquired growth 55 %

Acquisition of Mediplast and Fenno Medical July 2015Acquisition signed of V-Tech and Esthe-Tech March 2016

Signed agreement Leica Biosystems SE, DK, April 2016

New share issue in April of 300 MSEK

12

Market update Q4 2015/16

The market is developing positively, with growing demand from both health care and research.

The trend in the Nordic region reflects the increasing healthcare needs of a growing and aging population

In all of the Nordic countries, the trend is shifting towards larger contracts with public services, resulting in increased competition while squeezing margins in certain product areas

Sweden continued investments in clinical research

13

Q4 report (January - March 31, 2016)Group

Organic sales growth of 4% and acquired growth of 54% from the acquisitions of Mediplast and Fenno Medical on July 1, 2015

EBITA margin of 8.9% (10.2% excluding one off costs for the spin-off amounting to SEK 5.9m)

EBITA margin compression (excl. one off costs) primarily caused by a shift in product mix from the lower margin acquired businesses

302

47212.5%

8.9%

Q32014/15

Q32015/16

Net sales EBITA margin

295 303

12.3% 12.5%

Q32014/15

Q32015/16

Net sales EBITA margin

7

169

11.8%

6.9%

Q32014/15

Q32015/16

Net sales EBITA margin

Organic sales growth of 3% primarily driven by new technologies within the diagnostics segment

EBITA margin supported by stronger sales of equipment and supplies to healthcare and research laboratories, in particular to research within cell- and molecular biology

Net sales increased to SEK 169m as a result of the acquisitions of Mediplast and FennoMedical on July 1, 2015

Underlying performance for Mediplast and Fenno Medical in-line with previous year

EBITA margin impacted by:‒ Group allocated costs‒ Product mix and currency effects from the

acquisitions

LabTech MedTech

Note: AddLife Q3 data is based on publicly available data from Addtech’s Q3 report.

14

~450

906984

1,057

1,394

2004/05 2012/13 2013/14 2014/15 LTM Dec 31, 2015

~28

110 116 120129

~6%

12.1% 11.8% 11.3%

9.2%

2004/05 2012/13 2013/14 2014/15 LTM Dec 31,2015

EBITA EBITA-margin %

Group net sales and EBITA developmentNet sales development 2012/13 – 2015/16

EBITA development 2012/13 – LTM December 31, 2015

Comments

Comments

Above market growth (4%(1)) 2012/13 – LTM Dec. 31, 2015, incl. acquisitions

Mediplast and Fenno Medical are included in the financials from July 1, 2015

Net sales increase during first 9m of 2015/16 of 44%, of which 4% organic and 40% acquired growth from the acquisitions of Mediplast and Fenno Medical

Net sales increase 2012/13 – LTM Dec. 31, 2015 of 17% CAGR, of which 6% organic growth

Stable demand – margin compression 2012/13-2014/15 mainly driven by price pressure in larger tenders

EBITA-margin compression in LTM Dec. 31, 2015 primarily driven by change in product mix from the acquisitions of Mediplast and Fenno Medical

Adjusted EBITA margin LTM Dec. 31, 2015 amounted to 9.9%

One-off costs affecting EBITA related to the LexAsea transaction and the acquisitions of Mediplast and Fenno Medical, amounted to SEK 5.9m and SEK 3.1m respectively

Note: Revenue and EBITA for 2004/05 reflect approximate financials for Meditech which was acquired from B&B Tools in March 2005 and today is part of AddLife . Summary financial data – see page 39 for additional detail. (1) ADL Market Report.

15

894960

1,032 1,060

2012/13 2013/14 2014/15 LTM Dec 31,2015

107 112 117 114

11.9% 11.6% 11.3% 10.8%

2012/13 2013/14 2014/15 LTM Dec 31,2015

EBITA EBITA-margin %

Business area overview – LabTechNet sales development 2012/13 – LTM December 31, 2015

EBITA development 2012/13 – LTM December 31, 2015

Comments

Comments

Overall stable market environment in the LabTech segment

Growth primarily driven by stronger demand for diagnostic equipment and reagents in the Nordic healthcare sector

Demand from health care and research laboratories for equipment and consumables has improved

Higher competition has reduced margins in certain product segments

EBITA margin compression driven mainly by change in product mix, incl. increase in share of instrument sales

Note: Summary financial data – see page 39 for additional detail.

16

3 4 4

21

23.3%

15.5% 15.7%

6.4%

2012/13 2013/14 2014/15 LTM Dec 31, 2015

EBITA EBITA-margin %

13 24 25

334

2012/13 2013/14 2014/15 LTM Dec 31, 2015

Business area overview – MedTechNet sales development 2012/13 – LTM December 31, 2015

EBITA development 2012/13 – LTM December 31, 2015

Comments

Comments

Essentially reflects Mediplast and Fenno Medical (6 months)

Stable market environment in Sweden

Finnish market is more challenging

Increase in exports outside of the Nordic countries

Lower EBITA-margin due to shift in product mix from the acquisitions of Mediplast and FennoMedical

The underlying performance of Mediplast and Fenno Medical was in line with previous year, however the EBITA margin was impacted by:

‒ SEK 3.1m in acquisition related costs

‒ Group allocated costs

‒ Seasonal effect from slow Q2 (Jul-Sep)

Does not include Mediplast and Fenno Medical

Note: Summary financial data – see page 39 for additional detail.

17

SEK ~300 million (before transaction costs) with preferential rights for shareholders

RoosGruppen AB, Anders Börjesson (and family) and Tom Hedelius have committed to take their pro rata share (~18.5% of capital and ~38.0% of votes)

The purpose of the rights issue is to create an economic base for continued profitable growth through acquisitions

Balance sheet and illustrative impact rights issueIllustrative impact of SEK ~300 million rights issue (assuming fully subscribed)

Note: (1) In connection with the listing of AddLife, all dealings with Addtech will be netted and settled. As such, total equity and liabilities will decrease from reported SEK 1,444m on Dec. 31, 2015 to SEK 1,273m after netting. (2) Illustrative example only. Proceeds from the rights issue assumed to be used for debt repayment.

ILLUSTRATIVE As reportedNetting of balances

w. Addtech(1) Post rights issue (2)

SEKm 2015-12-31 2015-12-31 2015-12-31

Balance sheet items

Equity 321 321 621

Net debt 642 642 342

Total Equity & Liabilities 1,444 1,273 1,273

Key balance sheet ratios

ND / Equity 2.0x 2.0x 0.6x

Equity ratio 22% 25% 49%

ND/LTM EBITDA 4.7x 4.7x 2.4x

18

Selected key financial ratios

Note: Summary financial data – see page 39 for additional detail.(1) Financial rations are calculated including non-controlling interests included in equity

31 Dec 15 31 Mar 15 31 Mar 14 31 Mar 13

EBITA margin, % 9.2 11.3 11.8 12.1

Profit growth, EBITA, % 9.1 3.5 5.5 15.8

Return on working capital (P/WC), % 65.8 94.0 97.5 103.1

Return on equity, %1) 26.9 30.1 27.7 25.0

Financial net liabilities, SEKm 641.5 18.2 13.4 -27.5

Financial net liabilities/EBITDA, multiple 4.7 0.1 0.1 -0.2

Net debt/ equity ratio, multiple1) 2.0 0.1 0.0 -0.1

Shareholders equity 320.7 263.3 271.6 293.3

Equity ratio, %1) 22.2 40.9 44.3 48.2

Shareholders' equity per share, SEK1) 16.28 16.46 16.98 18.39

Number of shares outstanding at end of the period, ’000s 19,694 15,892 15,892 15,892

Number of employees at end of the period 423 286 280 273

12 months ending

Appendix